The Polypill in the prevention of cardiovascular disease

Preventive Medicine

Volumn 52, Issue 1, 2011, Pages 16-17

  Wald, David S ^a   Wald, Nicholas J ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; CARDIOVASCULAR AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL PRACTICE; COUGHING; DRUG EFFICACY; DRUG FORMULATION; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG UTILIZATION; DRUG WITHDRAWAL; HIGH RISK POPULATION; HUMAN; NOTE; PATIENT COMPLIANCE; PHYSICIAN ATTITUDE; PILL; POLYPILL; PRESCRIPTION; PRIMARY PREVENTION; PRIORITY JOURNAL; RISK REDUCTION;

ANTIHYPERTENSIVE AGENTS; ASPIRIN; CARDIOVASCULAR DISEASES; DRUG COMBINATIONS; EVIDENCE-BASED MEDICINE; FOLIC ACID; HEMATINICS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PLATELET AGGREGATION INHIBITORS; PRIMARY PREVENTION; UNITED STATES;

EID: 78650577158     PISSN: 00917435     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ypmed.2010.11.015     Document Type: Note

References (14)

1. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009, 373:1849-1860. Antithrombotic Trialists' (ATT) Collaboration.
2. BMJ Rapid Responses 2003, full#responses. http://www.bmj.com/content/326/7404/1419.
3. Derry S., Loke Y.K. Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis. BMJ 2000, 321:1183.
4. Law M.R., Wald N.J., Rudnicka A.R. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 2003, 326:1423-1427.
5. Law M.R., Wald N.J., Morris J.K., Jordan R.E. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 2003, 326:1427-1431.
6. Malekzadeh F., Marshall T., Pourshams A., et al. A pilot double-blind randomised placebo-controlled trial of the effects of fixed-dose combination therapy ('polypill') on cardiovascular risk factors. Int. J. Clin. Pract. 2010, 64:1220-1227.
7. McQuaid K.R., Laine L. Systematic review and meta-analysis of adverse events of low-dose aspirin and clopidogrel in randomized controlled trials. Am. J. Med. 2006, 119:624-638.
8. Polypill Prevention Programme. http://www.wolfson.qmul.ac.uk/polypill/index.html.
9. Smith R. The most important BMJ for 50years?. BMJ 2003, 326. (Published 25 June 2003). 10.1136/bmj.326.7404.0-f.
10. The Indian Polycap Study (TIPS). Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial. Lancet 2009, 373(9672):1341-1351.
11. Viera A., Sheridan S., Edwards T. et al., in press. Acceptability of a Polypill Approach to Prevent Cardiovascular Disease Among a Sample of U.S. Physicians. Prev Med. 52, 10-15.
12. Wald D.S., Wald N.J. The Polypill in the primary prevention of cardiovascular disease. Fundam. Clin. Pharmacol. 2010, 24:29-35.
13. Wald N.J., Law M.R. A strategy to reduce cardiovascular disease by more than 80%. BMJ 2003, 326:1419-1423.
14. Wald N.J., Hackshaw A.K., Frost C.D. When can a risk factor be used as a worthwhile screening test?. BMJ 1999, 319:1562-1565.